Gradient Echo MRI for Alzheimer Amyloid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's Disease, such as PET scans, are expensive, invasive, and not widely available, and lack non-invasive approaches for early detection of brain tissue pathology and preclinical changes.
Innovation Solution
The use of gradient echo magnetic resonance imaging (MRI) techniques, specifically GEPCI, to measure tissue-specific R2* and R2t* values in specific brain regions, allowing for the detection of β-amyloid accumulation and loss of cellular integrity, which serves as a biomarker for Alzheimer's Disease, and differentiation between normal, preclinical, and mild AD stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PET scans are used to detect amyloid plaques, then detection precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent replaces the complex PET imaging system with a magnetic resonance imaging (MRI) system that uses magnetic fields and radio waves instead of radioactive tracers. The MRI scanner with gradient echo sequences substitutes the PET scanner's detection mechanism, achieving amyloid plaque detection through magnetic susceptibility effects rather than radioactive decay detection.
Solution Approach 2:
The patent employs a widely available MRI scanner platform that is already present in most hospitals, replacing the specialized and expensive PET scanner. The MRI system uses standard clinical imaging technology rather than dedicated research-grade PET equipment, making the detection method more accessible and cost-effective.
2Measurement precision
If PET scans are used to detect amyloid plaques, then detection precision is improved, but harmful factors increase due to radiation exposure
Solution Approach 1:
The patent replaces the radiation-based PET detection mechanism with a non-ionizing magnetic resonance imaging system. The MRI scanner uses magnetic fields and radiofrequency pulses that do not ionize tissue, eliminating the harmful radiation exposure while maintaining the ability to detect amyloid plaques through magnetic susceptibility differences.
3Measurement precision
If PET scans are used to detect amyloid plaques, then detection precision is improved, but ease of operation deteriorates due to limited availability
Solution Approach 1:
The patent utilizes the MRI scanner's existing multiple functions by applying gradient echo sequences with susceptibility-weighted imaging parameters. The same MRI system that performs routine anatomical imaging is repurposed for amyloid plaque detection, eliminating the need for separate specialized equipment and making the detection capability universally available at facilities with standard MRI scanners.
4Ease of operation
If gradient echo MRI is used to measure R2* values, then ease of operation is improved, but measurement precision deteriorates due to background field inhomogeneities
Solution Approach 1:
The patent extracts and isolates the tissue-specific R2* signal from the total measured signal by separating it from background field inhomogeneity effects. Through mathematical decomposition of the signal decay, the method extracts the microstructural tissue information (R2t*) from the macroscopic field effects, achieving precise amyloid detection despite the presence of background inhomogeneities.
Solution Approach 2:
The patent introduces mathematical modeling and signal processing algorithms as intermediaries between the raw MRI signal and the final R2* measurement. These computational tools mediate the relationship by correcting for field inhomogeneities and isolating the tissue-specific relaxation component, enabling accurate measurement without requiring physical modification of the imaging system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a cost-effective, widely accessible, and non-invasive method for diagnosing Alzheimer's Disease by accurately measuring β-amyloid accumulation and cellular integrity, enabling early detection and differentiation of AD stages without radiation exposure.
Implementation Method 1
obtaining a scan of the brain of a subject using gradient echo magnetic resonance imaging (MRI) technique
Implementation Method 2
measuring tissue specific R2* values in specific brain regions
Implementation Method 3
gradient echo plural contrast imaging (GEPCI)
Implementation Method 4
an increase in tissue specific R2* relative to a normal control (ΔR2*) indicates that the subject has increased accumulation of β-amyloid
Data Source
AI summary
Disclosed are systems, biomarkers, and methods for the diagnosis of Alzheimer's Disease.